TABLE 4.
Incidence rates of osteosarcoma, incidence rate ratio, and incidence rate difference
| Statistic | Teriparatide cohort(n = 153 316) | Comparator cohort(n = 613 247) |
|---|---|---|
| Number of matched osteosarcoma cases by linkage to the participating cancer registries, n | 0 | n < 11 |
| Total person‐time of observation (years), PT | 585 955 | 2 212 036 |
| Adjusted for the coverage fraction (PT × 0.68) | 397 000 | 1 498 715 |
| Among patients from only the states with participating cancer registries a | 378 631 | 1 426 199 |
| Incidence rates per million person‐years (n/PT × 1 000 000) | ||
| Adjusted for the coverage fraction (95% CI) | 0.00 (0.00‐9.29) | Suppressed (1.47‐8.71) |
| Among patients from only the states with participating cancer registriesa (95% CI) | 0.00 (0.00‐9.74) | Suppressed (1.54‐9.16) |
| Incidence rate ratio | ||
| Adjusted for the coverage fraction (95% CI) | 0.00 (0.00‐3.21) | — |
| Primary study population with a 6‐month latency period | ||
| Incidence rate ratio | ||
| Adjusted for the coverage fraction (95% CI) | 0.00 (0.00‐3.19) | — |
| Primary study population requiring two teriparatide prescriptions | ||
| Incidence rate ratio | ||
| Adjusted for the coverage fraction (95% CI) | 0.00 (0.00‐3.54) | — |
Abbreviations: CI = confidence interval.
Note: To protect patient privacy, non‐zero cell counts <11 cannot be disclosed for Medicare data.
a
100 033 patients in the teriparatide cohort and 400 119 patients in the comparator cohort were from states with participating cancer registries.